Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
出版年份 2020 全文链接
标题
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
作者
关键词
-
出版物
Cancers
Volume 12, Issue 7, Pages 1727
出版商
MDPI AG
发表日期
2020-06-30
DOI
10.3390/cancers12071727
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapies for Melanoma: A New Standard of Care?
- (2016) Keiran S. M. Smalley et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
- (2015) K E Duncan et al. EYE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
- (2015) F Ravandi et al. Blood Cancer Journal
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- 604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
- (2012) A. Awada et al. EUROPEAN JOURNAL OF CANCER
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
- Epidemiology and risk profile of heart failure
- (2010) Anh L. Bui et al. Nature Reviews Cardiology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now